We recently compiled a list of the 12 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are ...

For example, the Merck KGaA (ETR:MRK) share price is up 39% in the last five years, slightly above the market return. In comparison, the share price is down 13% in a year. So let's assess the ...

A month has gone by since the last earnings report for Merck (MRK). Shares have added about 3.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. . Shareholders who purchased shares of MRK ...

Germany’s Merck KGaA (MRK: DE) returned to profitable growth in 2024 and delivered on its guidance for the year.

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

AI names and growth stocks have stumbled in early 2025. 2024’s big stock market winners are among the worst performers in recent weeks. AI stocks have plunged double digits amid a wave of challenging ...

EU mid-market update: USD/JPY at 5-month low; Opening optimism from one-month delay to auto tariffs but focus is on ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

FDA nominee Marty Makary pledges to review the cancellation of a key flu vaccine meeting, addressing concerns over ...

Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on Halozyme (HALO – Research Report) today and set a price target of $53.00.

Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...